Endocrine Response in Women With Invasive Lobular Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

DRUG

Anastrozole

DRUG

Fulvestrant

Trial Locations (12)

10467

ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, The Bronx

15213

Josh Plassmeyer, Pittsburgh

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

20007

Georgetown University Medical Center, Washington D.C.

27514

University of North Carolina at Chapel Hill, Chapel Hill

35294

UAB Comprehensive Cancer Center, Birmingham

55905

Mayo Clinic, Rochester

60637

University of Chicago Medical Center, Chicago

77030

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston

77064

University of Texas MD Anderson Cancer Center, Houston

94143

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

98109

Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
lead

Priscilla McAuliffe

OTHER

NCT02206984 - Endocrine Response in Women With Invasive Lobular Breast Cancer | Biotech Hunter | Biotech Hunter